Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.22.14_SUPPL.7062PMID 28016100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response

  2016cites this paper
• Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

  2016cites this paper
• Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

  2014cites this paper
• Pulmonary toxicities of tyrosine kinase inhibitors.

  2011cites this paper
• Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer

  2010cites this paper
• Time to move beyond clinical and pathologic classification of BAC.

  2010cites this paper
• Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?

  2010cites this paper
• Review: Adjuvant therapy for resected non-small cell lung cancer

  2009cites this paper
• First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

  2009cites this paper
• New directions in the management of advanced pancreatic cancer: a review

  2008cites this paper
• Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group

  2008cites this paper
• Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

  2008cites this paper
• Targeted therapies in bronchioloalveolar carcinoma

  2008cites this paper
• Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

  2008cites this paper
• EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

  2008cites this paper
• DEFINITIVE MANAGEMENT OF INOPERABLE NON–SMALL CELL LUNG CANCER

  2008cites this paper
• Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.

  2007cites this paper
• Recent advances in targeted therapy for non-small cell lung cancer

  2007cites this paper
• Combination of Standard Chemotherapy and Targeted Agents

  2007cites this paper
• Erlotinib in non-small-cell lung cancer

  2007cites this paper
• Independent Review of Interstitial Lung Disease Associated with Death in TRIBUTE (Paclitaxel and Carboplatin with or without Concurrent Erlotinib) in Advanced Non-small Cell Lung Cancer

  2007cites this paper
• Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

  2007cites this paper
• The place of targeted therapy in the patient management of non-small cell lung cancer.

  2007cites this paper
• Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

  2007cites this paper
• Carcinome bronchio-alvéolaire (CBA) et adénocarcinome pulmonaire avec composante bronchio-alvéolaire (ADC-CBA) : un continuum anatomoclinique

  2007cites this paper
• Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?

  2007cites this paper
• Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer.

  2007cites this paper
• Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.

  2006cites this paper
• Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.

  2006cites this paper
• Emerging approaches to advanced bronchioloalveolar carcinoma

  2006cites this paper
• Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

  2006cites this paper
• Biological and clinical implications of EGFR mutations in lung cancer

  2006cites this paper
• Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.

  2006cites this paper
• Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.

  2006cites this paper
• A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

  2006cites this paper
• Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations.

  2006cites this paper
• The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases

  2006cites this paper
• Clinical experience with gefitinib: an update.

  2006cites this paper
• A review of erlotinib and its clinical use

  2006cites this paper
• bronchioloalveolar carcinoma : Improvement in survival after release of the 1999 WHO classification of lung tumors

  2006cites this paper
• Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.

  2006cites this paper
• Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.

  2006cites this paper
• Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma

  2006cites this paper
• A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy

  2006cites this paper
• Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia–Pacific region

  2006cites this paper
• Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a clinical practice guideline

  2006cites this paper
• Non-small-cell lung cancer in the elderly.

  2006cites this paper
• Emerging Approaches to Advanced ar Carcinoma

  2006cites this paper
• Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review

  2006cites this paper
• Targeting HER1/EGFR in cancer therapy: experience with erlotinib.

  2005cites this paper
• Neue molekulare Therapien beim nichtkleinzelligen Lungenkarzinom am Beispiel der EGFR/HER1-Inhibition

  2005cites this paper
• State of the Art in Therapy for Non-Small Cell Lung Cancer

  2005cites this paper
• Molecularly-targeted therapies for non-small cell lung cancer

  2005cites this paper
• How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.

  2005cites this paper
• First-line treatment for advanced non-small-cell lung cancer.

  2005cites this paper
• Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers

  2005cites this paper
• Tyrosinkinaseinhibition

  2005cites this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cites this paper
• Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer

  2005cites this paper
• Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment

  2005cites this paper
• Therapeutic targeting of receptor tyrosine kinases in lung cancer

  2005cites this paper
• Erlotinib in the treatment of non-small cell lung cancer

  2005cites this paper
• The Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 1, Gefitinib and Erlotinib for Non-Small Cell Lung Cancer

  2005cites this paper
• Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.

  2005cites this paper
• Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer

  2005cites this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cites this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cites this paper
• Practical management of patients with non-small-cell lung cancer treated with gefitinib.

  2005cites this paper
• Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.

  2004cites this paper
• Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.

  2004cites this paper
• Bronchoalveolar carcinoma: current treatment and future trends.

  2004cites this paper
• Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.

  2004cites this paper
• Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.

  2004cites this paper
• Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.

  2004cites this paper